^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | veliparib (ABT-888) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
Excerpt:
...- Patients with known or suspected germline mutation in BRCA1 or BRCA2 are eligible to participate...
Trial ID:
Source:
Title:
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Excerpt:
...Prevalence of BRCA1 and BRCA2 Mutations (Somatic or Germline)`Homologous Recombination Deficiency (HRD) Score`Genomic Alterations Identified by the BROCA-homologous Recombinant (HR) Assay...
Trial ID:
More C2 evidence
Source:
Title:
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Excerpt:
...- Have a documented BRCA1/2 mutation and a BRCA related malignancy (primarily breast or ovarian cancers, but also may include prostate or pancreatic cancers);...
Trial ID:
Source:
Title:
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Excerpt:
...- BRCA1/2 mutation and a BRCA-related malignancy...
Trial ID:
Source:
Title:
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Excerpt:
...- Male or female patients with cytologically or histologically confirmed locally advanced or metastatic pancreas adenocarcinoma with a BRCA1 or 2 or PALB2 mutation confirmed by report from Myriad Genetics (United States of America [USA]); reports from other molecular diagnostic companies can be used to confirm mutations as well; BRCA 1 or 2 or PALB2 mutation can be confirmed locally for all international sites...
Trial ID:
Less C2 evidence
Source:
Title:
A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.
Published date:
01/24/2020
Excerpt:
Exploratory analyses (combined Arms): Med OS if > 4 m platinum → PARPi: 23 m (95%CI 6.5- 53.9). Med OS by BRCA: BRCA1: 14 m (8.1- 18.5); BRCA2: 20.2 m (12.3- 24.4)...GC +/- V very active in gBRCA/PALB2 mut PDAC with high RR, PFS, OS with both A, B significantly exceeding threshold RR.
Secondary therapy:
cisplatin + gemcitabine
Trial ID:
Source:
Title:
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
Excerpt:
The objective response rate in the BRCA+ cohort was 7 of 9 (77.8%). The median overall survival for BRCA+ patients was 23.3 months (95% confidence interval [CI], 3.8-30.2 months).
DOI:
10.1002/cncr.31218
Trial ID:
